bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
Go back to bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung| (NASDAQ: BIAF) | Delayed: 8.93 -6.34 (41.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.27 | 52 Week High | $ | |||
| Open | $10.63 | 52 Week Low | $ | |||
| Day High | $10.63 | P/E | N/A | |||
| Day Low | $8.36 | EPS | $ | |||
| Volume | 2,405,595 | |||||
| (NASDAQ: BIAFW) | Delayed: 0.60 -0.1 (14.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.70 | 52 Week High | $ | |||
| Open | $0.98 | 52 Week Low | $ | |||
| Day High | $0.98 | P/E | N/A | |||
| Day Low | $0.55 | EPS | $ | |||
| Volume | 48,446 | |||||

